This paper examines the variety of corporate venturing activities in the pharmaceutical and life science sectors, identifies the range of initiators, motives and structures, and evaluates the potential opportunities for professional venture capital firms. On the one hand, pharmaceutical companies need to maintain the new product pipeline that has increased the demand for technology acquisition, and on the other, mergers and rationalization within the sector have resulted in a significant growth in technology divestment. Both trends have boosted corporate venturing activity. The study examines the venture activities of nine pharmaceutical firms, fourteen life science companies and seven corporate venture capital funds. The authors conclude that, while there is a wide range of venturing options, there is considerable confusion in the industry over ends and means. Specifically, many firms have failed to differentiate sufficiently between strategic, financial and operational goals, and have therefore created inappropriate forms of corporate venture.
Atuaheme-GimaK.PattersonP. (1993), ‘Managerial perspectives of technology licensing as an alternative to internal R&D in new product development: An empirical investigation’, R&D Management, Vol 23, pp 327–336.
2.
BindingK.McCubbinC.DoyleL. (1998), Technology Transfer in the UK Life Sciences, Arthur Andersen, Cambridge.
BlockZ.MacMillanI. C. (1993), Corporate Venturing: Creating New Businesses Within the Firm, Harvard Business School Press, Boston, MA.
5.
BlockZ.SubbanarasimhaP. N. (1989), Corporate Venturing: Practices and Performance in the US and Japan, working paper, Center for Entrepreneurial Studies, Stern School of Business, New York University, NY.
6.
BurgelmanR. A.MaidiqueM. A. (1988), Strategic Management of Technology and Innovation, Irwin, Chicago, IL.
7.
BurgelmanR. A.SaylesL. R. (1986), Inside Corporate Innovation, Macmillan, London.
8.
CarrG. (1998), ‘The pharmaceutical industry survey: The alchemists’, The Economist, 21 February.
9.
DavidsonA. (1998), ‘Investment status of biopharmaceuticals’, Drug Discovery Today, Vol 3, pp 391–392.
10.
DewdneyJ. M.SmithR. A. G. (1998), ‘Putting a new spin on R&D assets in the pharmaceutical industry’, Drug Discovery Today, Vol 3, pp 353–354.
HardymonG. F.DeNinoM. J.SalterM. S. (1983), ‘When corporate venture capital doesn't work’, Harvard Business Review, May/June, pp 114–120.
13.
LangJ. W. (1996), ‘Strategic alliances between large and small high-tech firms, the small firm licensing option’, International Journal of Technology Management, Vol 12, pp 796–807.
14.
BrothersLehman (1997), Pharmaceutical Company Valuation, Lehman Global Pharmaceutical Research, London.
15.
LeiD.SlocumJ. W. (1992), ‘Global strategy: Competence building and strategic alliances’, California Management Review, Vol 35, pp 81–97.
16.
London Stock Exchange (1997), Listing Rules, London Stock Exchange, London.
17.
MacMillanI. C.BlockZ.SubbanarasimhaP. N. (1986), ‘Corporate venturing: Alternatives, obstacles encountered and experience effects’, Journal of Business Venturing, Vol 1, pp 177–192.
18.
MartinM. J. C. (1994), Managing Innovation and Entrepreneurship in Technology, John Wiley & Sons, New York.
19.
MasonC.HarrisonR. (1994), ‘The role of informal and formal sources of venture capital in financing of technology-based SMEs in the United Kingdom’, in OakeyR. P., ed, New Technology-Based Firms in the 1990s, Paul Chapman, London.
20.
MasonC.HarrisonR. (1999), ‘Venture capital: Rationale, aims and scope’, Venture Capital, Vol 1, No 1, pp 1–46.
21.
McKinseyCompany (1997), Raising Innovation to New Heights in Pharmaceutical Research, McKinsey & Company Inc, London.
22.
WaterhousePrice (1998), Global Market and Deal Survey: Pharmaceutical Sector 1997, Price Waterhouse, London.
23.
ShraderR. C.SimonM. (1997), ‘Corporate versus independent new ventures: Resource, strategy, and performance differences’, Journal of Business Venturing, Vol 12, pp 47–66.
24.
SiegelR.SiegelE.MacMillanI. C. (1988), ‘Corporate venture capitalists: Autonomy, obstacles and performance’, Journal of Business Venturing, Vol 3, pp 233–247.
25.
SlatterS. (1992), Gambling on Growth, John Wiley & Sons, Chichester.
26.
SykesH. B. (1986), ‘Lessons from a new ventures program’, Harvard Business Review, May/June, pp 43–59.
27.
SykesH. B. (1990), ‘Corporate venture capital success’, Journal of Business Venturing, Vol 5, pp 37–47.
28.
TiddJ.BessantJ.PavittK. (1997), Managing Innovation: Integrating Technological, Market and Organizational Change, John Wiley & Sons, Chichester.
29.
TiddJ.TaurinsS. A. (1999), ‘Learn or leverage? Strategic diversification & organisational learning through corporate ventures’, Journal of Creativity and Innovation Management, Vol 8, No 2, pp 122–129.
30.
TiddJ.TrewhellaM. J. (1997), ‘Organisational and technological antecedents for knowledge acquisition and learning’, R&D Management, Vol 27, pp 359–375.
Withers (1995), Gateway to Growth: A Study of Corporate Venturing, Withers Solicitors, London.
33.
Withers (1997), Window on Technology: Corporate Venturing in Practice, Withers Solicitors, London.
34.
ZahraS. A. (1996), ‘Technology strategy and new venture performance: A study of corporate-sponsored and independent biotechnology ventures’, Journal of Business Venturing, Vol 11, pp 289–321.
